Enjoy complimentary customisation on priority with our Enterprise License!
It has been observed that polymyositis is characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles. It mostly affects adults in the age group of 31-60 years and is rarely seen in people under 18 years of age. The condition mainly develops when an attack on muscle tissue occurs by white blood cells called T lymphocytes, which are produced by the immune system to fight infection. Furthermore, symptoms of the disease also include muscle weakness, aching or painful muscles, shortness of breath, and difficulty in swallowing and speaking, and heart arrhythmias. According to the Committee for Orphan Medicinal Products (COMP) in November 2014, polymyositis affected approximately 0.4 people in 10,000 people in the EU region. Consequently, with rising incidences of the disease, the drug development for polymyositis is expected to increase considerably during the next few years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for polymyositis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of polymyositis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
The subcutaneous route of administration (ROA) involves the application of the drug is delivered into the subcutis, which will have a more direct effect on the target cells.
According to this pipeline analysis report, most of the molecules that are currently in the drug development for polymyositis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.